Luye Pharma Group Ltd.

Symbol: 2186.HK

HKSE

3.02

HKD

Market price today

  • 19.0836

    P/E Ratio

  • 1.7261

    PEG Ratio

  • 11.36B

    MRK Cap

  • 0.00%

    DIV Yield

Luye Pharma Group Ltd. (2186-HK) Financial Statements

On the chart you can see the default numbers in dynamics for Luye Pharma Group Ltd. (2186.HK). Companys revenue shows the average of 2789.84 M which is 0.168 % gowth. The average gross profit for the whole period is 2107.15 M which is 0.187 %. The average gross profit ratio is 0.771 %. The net income growth for the company last year performance is -0.119 % which equals 0.338 % % on average for the whole company history.,

Balance Sheet

Diving into the fiscal trajectory of Luye Pharma Group Ltd., we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to 0. A look back at the past year reveals a total asset change of 0.051. In the realm of current assets, 2186.HK clocks in at 10703.282 in the reporting currency. A significant portion of these assets, precisely 8522.266, is held in cash and short-term investments. This segment shows a change of 0.537% when juxtaposed with last year's data. Long-term investments of the company, while not its focus, stand at 1968.434, if any, in the reporting currency. This indicates a difference of -193.448% from the last reporting period, reflecting the company's strategic shifts. The debt profile of the company shows a total long-term debt of 3228.193 in the reporting currency. This figure signifies a year_over_year change of -0.075%. Shareholder value, as depicted by the total shareholder equity, is valued at 12531.185 in the reporting currency. The year over year change in this aspect is 0.231%. A deeper dive into the company's financials reveals additional details. The net receivables are valued at 2354.899, with an inventory valuation of 827.86, and goodwill valued at 1041.93, if any. The total intangible assets, if present, are valued at 6317.88. Account payables and short-term debt are 767.19 and 5195.75, respectively. The total debt is 8423.95, with a net debt of 2769.14. Other current liabilities amount to 2193.37, adding to the total liabilities of 11962.22. Lastly, the referred stock is valued at 0, if it exists.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201120102009200820072006200520042003

balance-sheet.row.cash-and-short-term-investments

30442.48522.35544.35510.3
5406.3
5188.1
4862.6
3841.4
2747.4
3206.4
2177.3
343.1
330.5
454.6
320.4
118.5
142.9
95.6
70.4
132.7
54.1

balance-sheet.row.short-term-investments

8899.942867.53220.53072.1
1540.9
2862.6
3189.7
2575.5
2349.6
2362.7
1845.4
10
79
54.5
45.1
0
0
0
0
0
0

balance-sheet.row.net-receivables

9083.12354.91783.71765.1
1553.1
1813
0
0
0
0
0
0
493.4
366.6
355.6
269.5
233.9
169.8
138.3
95.8
72.3

balance-sheet.row.inventory

3262.94827.9772.9746.3
612.3
614.6
585.6
420.4
452.7
285.6
251.2
234.7
105.4
73.3
57.6
56
42.3
33.6
29.1
28.6
16.3

balance-sheet.row.other-current-assets

14658.343009.94658.75059.1
3830.7
3763.4
3227.1
2034.2
2082.4
1579.5
1097.5
1074.5
0.9
0.9
1.7
2.2
46.2
36.3
15.9
5.4
19.4

balance-sheet.row.total-current-assets

47624.6510703.310785.810396.7
9970.4
9359.8
8675.3
6295.9
5282.5
5071.4
3526
1652.4
930.2
895.4
735.4
446.3
465.3
335.4
253.8
262.5
162.2

balance-sheet.row.property-plant-equipment-net

19926.445127.24909.14594.5
4339.3
4213.4
3195.6
2463.9
1969.5
1430.8
1320.6
1162.1
669.7
319.4
205
152.4
147.1
106.7
114.9
94.6
99.6

balance-sheet.row.goodwill

4170.881041.91003.4985.4
1056.6
1038.1
1040.9
1036.9
995.9
347.4
347.4
347.4
359.4
188.2
188.2
165.9
168.7
44.4
5.9
0
0

balance-sheet.row.intangible-assets

25053.856317.95984.75441.8
4770
4486.9
4445.1
828.7
855.7
126.2
145.9
136.3
406.5
340.5
367.1
200.4
222.1
48
8.7
9.4
10.3

balance-sheet.row.goodwill-and-intangible-assets

29224.747359.86988.16427.2
5826.6
5524.9
5485.9
1865.6
1851.6
473.6
493.2
483.7
765.8
528.7
555.3
366.3
390.8
92.4
14.6
9.4
10.3

balance-sheet.row.long-term-investments

1699.951968.4-2106.4-2489.9
-1469.4
-2790.8
-3106.1
-2534.7
-2341.1
-2355
-1837.7
-0.3
-72.9
-47
-40.5
0
119.6
9.1
4.5
0.5
0.5

balance-sheet.row.tax-assets

291.01144.6113.9133.1
114.7
93.9
98.4
94.2
93.8
69.4
83.3
79.4
58.5
22.9
21.3
6.9
5.1
1
0.5
0.7
0.2

balance-sheet.row.other-non-current-assets

4815.04187.43559.13520.4
1848.9
2912.6
3189.7
2575.5
2349.6
2362.7
2545.4
10.3
103.2
102.8
47.4
94.8
5.5
294.7
4.7
5.4
0.7

balance-sheet.row.total-non-current-assets

55957.1714787.413463.812185.4
10660.1
9954.1
8863.5
4464.5
3923.4
1981.5
2604.8
1735.1
1524.2
926.8
788.6
620.5
668
503.8
139.2
110.6
111.3

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

103581.8125490.724249.622582.1
20630.6
19313.9
17538.8
10760.4
9205.8
7052.9
6130.8
3387.5
2454.4
1822.2
1524
1066.7
1133.3
839.2
393
373
273.5

balance-sheet.row.account-payables

2864.67767.2559.9570.9
485.3
298.5
279.8
104.6
116.1
83.2
59
69.4
34.3
20.3
13.4
11.7
8.3
9.1
9.8
9.5
12

balance-sheet.row.short-term-debt

25899.195195.86839.85263.2
5642.9
3943.6
5290.5
2861.1
1623.7
502.2
304.9
735.9
453.8
264.1
170.7
65.8
137.3
28.9
10.7
49
88

balance-sheet.row.tax-payables

565.73294.9256.3205.1
358.1
260.2
223.8
249.4
216.5
159.4
122.5
100.4
32
12.3
9.7
3.6
1
0
0
0
0

balance-sheet.row.long-term-debt-total

10671.393228.22264.74227.6
4338.6
4122.3
847.6
0.2
0.4
0.5
0.6
9.4
2
1.3
30
74.9
115.8
0
0
8
37

Deferred Revenue Non Current

264.72103.6175209.4
185.7
131.9
149.6
107.6
147.3
115.2
106.6
78.7
2.5
2.4
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

94.99---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

10345.672193.42087.51496.1
1106
17.5
2408.8
57.8
5.4
25.2
37
74.4
28.3
18.8
2.1
57.6
2.8
4.5
20.5
2.6
27.7

balance-sheet.row.total-non-current-liabilities

13045.193824.43720.76138
5297.5
4395.6
1401.9
209.7
269.1
208
205
186.8
159
115
105.4
106.1
142.6
3.5
2.5
11.6
42.6

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

223.1770.638.542
24.7
29
0.2
0.4
0.5
0.6
0.1
0.1
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

52136.2211962.213207.913468.2
12531.6
9942.1
9604.8
3864.5
2643.8
1253.4
1093.2
1489.8
1050
574
429.2
244.9
356.8
111.1
43.5
89.7
170.4

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

1944.43486.1457455.8
418
420.6
421.3
427.3
427.3
427.3
427.3
81.2
81.2
81.2
81.2
81.2
0
0
0
0
0

balance-sheet.row.retained-earnings

14005.2306667.36061.8
6209.3
5688.4
0
0
2667.2
1930.9
1206.8
992.1
585.6
460.5
478.1
312.1
14.4
0
0
0
0

balance-sheet.row.accumulated-other-comprehensive-income-loss

16081.527885.8254.5534
501.5
381.9
-888.7
-735.1
-592.8
-348.2
-290.2
-232.8
-169.6
-145.3
-123.8
-111.2
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

15700.84159.32797.31436.4
762.4
2733.3
8275.8
7076.2
3926.8
3654
3563.8
928.6
780
730
551.8
539.2
761.5
727.6
345
272.1
96.3

balance-sheet.row.total-stockholders-equity

47731.9912531.2101768488.1
7891.2
9224.2
7808.4
6768.4
6428.5
5664
4907.6
1769
1277.2
1126.4
987.3
821.3
775.9
727.6
345
272.1
96.3

balance-sheet.row.total-liabilities-and-stockholders-equity

103581.8125490.724249.622582.1
20630.6
19313.9
17538.8
10760.4
9205.8
7052.9
6130.8
3387.5
2454.4
1822.2
1524
1066.7
1133.3
839.2
393
373
273.5

balance-sheet.row.minority-interest

3713.61997.3865.8625.8
207.8
147.7
125.6
127.5
133.5
135.6
130
128.7
127.2
121.7
107.4
0.6
0.6
0.6
4.5
11.3
6.9

balance-sheet.row.total-equity

51445.613528.511041.79113.9
8099
9371.8
7934
-
-
-
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

103581.81---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

Total Investments

7732.431968.41114.1582.2
71.5
71.9
83.6
40.8
8.5
7.7
7.7
9.7
6.1
7.5
4.7
92
119.6
9.1
4.5
0.5
0.5

balance-sheet.row.total-debt

36570.588423.99104.59490.8
9981.5
8065.9
6138.1
2861.4
1624.1
502.7
305.5
745.3
455.8
265.5
200.7
140.8
253.1
28.9
10.7
57
125

balance-sheet.row.net-debt

18731.272769.16780.87052.5
6116.1
5740.4
4465.3
1595.5
1226.3
-341
-26.3
412.2
204.3
-134.7
-74.6
22.3
110.2
-66.6
-59.7
-75.7
70.9

Cash Flow Statement

The financial landscape of Luye Pharma Group Ltd. has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of -0.122. The company recently extended its share capital by issuing 189.16, marking a difference of 6.380 compared to the previous year. Interestingly, a portion of the company's stock, specifically 0, was bought back by the company itself. This action resulted in a change of 0.000 from the previous year. Meanwhile, the company's account payables are currently standing at 18.77 in the reporting currency. The company's investing activities resulted in net cash usage, amounting to -1658308000.000 in the reporting currency. This is a shift of -0.517 from the previous year. In the same period, the company recorded 671.31, 91.8, and -8301.9, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of 0.000, with a year over year difference of 0.000. Furthermore, the company allocated 0 for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as 8166.89, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM2022202120202019201820172016201520142013201120102009200820072006200520042003

cash-flows.row.net-income

532.61669.8-74.6942.2
1771.7
1473.5
1116.3
974.7
898.1
725.5
383.2
201.1
195.4
166.2
62.1
59
80.9
90.2
71.8
42.6

cash-flows.row.depreciation-and-amortization

331.43671.3582510.9
442
317.2
249.8
140.9
115.2
110.4
100.4
79
70.2
44.8
0
41.2
15.1
11.7
11.1
10.3

cash-flows.row.deferred-income-tax

-914.590-311.9-505.9
-422.5
-411.5
-317.5
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

20.6425.45050.9
64.7
31.3
6.3
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

186.15319.8-418.1-300.3
-289.6
-486.2
-113.6
-308.4
-410.2
-375.5
38.1
113
50.9
-13.3
0
5.3
-4.8
-39.8
-38.5
-19.5

cash-flows.row.account-receivables

-403.05-18.8-211.8145
-166.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.inventory

-30.67-26.6-1344.9
-29
-165.3
32.3
-43.1
-34.4
-16.5
-92
-9.2
-14.5
3.9
0
3.5
-4.5
-0.7
-12.3
-3.3

cash-flows.row.account-payables

118.9818.8211.8-145
166.6
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

619.86346.4-284-305.2
-260.6
-320.9
-145.9
-265.4
-375.8
-359.1
130.1
122.1
65.4
-17.2
0
1.7
-0.3
-39.1
-26.3
-16.2

cash-flows.row.other-non-cash-items

-381.1-32.5355335.7
178.7
121.3
22.8
-215.2
-208.4
-141.3
-83.1
-68
-62.3
-34.6
43.8
33.1
-40.2
-19.3
3.6
7

cash-flows.row.net-cash-provided-by-operating-activities

689.73000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

-544.22-1163.7-1541.6-1519.9
-3223
-2484.5
-625.2
-319.1
-208.1
-289.3
-270.9
-338.2
-140.6
-24.5
-44.3
-14
-9.4
-29.4
-11.5
-13.2

cash-flows.row.acquisitions-net

0.110-808.5-450.8
-2085.1
-1655.2
-5.4
-1674.5
700
-700
2.1
-271.9
-46.2
1.3
0.4
-167.1
0
0
0
0

cash-flows.row.purchases-of-investments

-218.72-3485.9-3975.7-2859.2
-3073.6
-3958.8
-4676.4
-4554
-5919.3
-1840.5
-10
0
0
-45.1
0
0
0
-4
0
0

cash-flows.row.sales-maturities-of-investments

627.682899.519194153.8
3397.3
3326.1
4498.1
4610.6
5655.1
25.9
1
0
0
0.2
0
0
0
0
0
0

cash-flows.row.other-investing-activites

-78.0291.8970.7814.2
2292.8
1774.7
65.2
102.2
12.6
-174.9
-275.5
-33
-4.2
2
40.2
2.7
-335.1
-11.2
-3.6
0.5

cash-flows.row.net-cash-used-for-investing-activites

-78.02-1658.3-3436138.2
-2691.5
-2997.7
-743.7
-1834.9
240.3
-2978.8
-553.4
-643.1
-191.1
-66.2
-3.6
-178.3
-344.4
-44.6
-15.1
-12.7

cash-flows.row.debt-repayment

-561.84-8301.9-7536.7-5896.7
-6739.2
-5943.1
-2629.6
-2282.8
-1294.3
-2187
-1023.9
-448.7
-295.1
-164.7
-203
-161.8
-59
-49
-110
-106.3

cash-flows.row.common-stock-issued

1043.83189.21044.57326.7
8828.8
1.6
-281.2
0
0
3139.3
0
0
0
0
0
161.8
320.4
0
104.1
0

cash-flows.row.common-stock-repurchased

000-78
-8.8
-21.6
-178.1
0
0
0
0
0
-3.1
0
0
-2
59
0
42
0

cash-flows.row.dividends-paid

000-175.5
-376.8
-289.7
-212.6
-107
0
0
0
0
0
0
-14.4
-19.1
-16.5
-14.3
-0.8
-17.4

cash-flows.row.other-financing-activites

1522.958166.98371.1-922.6
-97.2
8657.4
4034
3209.8
1345.6
1705.5
1111.2
618.2
359.9
224.6
90.7
108.3
14.6
2.7
10.3
127.4

cash-flows.row.net-cash-used-provided-by-financing-activities

1522.9554.11878.9254
1606.8
2404.6
732.6
820
51.3
2657.8
87.3
169.5
61.7
59.9
-126.7
87.1
318.6
-60.6
45.6
3.7

cash-flows.row.effect-of-forex-changes-on-cash

14.37-164.1-52.4112.4
-7.5
-45.5
-84.9
-23
5.5
0.6
-3.5
0
0
0
0
0
0
0
0
0

cash-flows.row.net-change-in-cash

3254.94-114.5-1427.11538
652.6
407
868.1
-445.9
691.8
-1.3
-30.9
-148.6
124.8
156.8
-24.4
47.3
25.2
-62.3
78.5
31.4

cash-flows.row.cash-at-end-of-period

5899.822323.72438.33865.4
2325.4
1672.9
1265.9
397.8
843.7
331.9
333.1
251.5
400.1
275.3
118.5
142.9
95.6
70.4
132.7
54.1

cash-flows.row.cash-at-beginning-of-period

2644.892438.33865.42327.3
1672.9
1265.9
397.8
843.7
151.9
333.1
364
400.1
275.3
118.5
142.9
95.6
70.4
132.7
54.1
22.8

cash-flows.row.operating-cash-flow

689.731653.8182.41033.4
1744.9
1045.6
964.1
592
394.7
319.1
438.6
325
254.2
163.2
105.9
138.5
51
42.9
48
40.3

cash-flows.row.capital-expenditure

-544.22-1163.7-1541.6-1519.9
-3223
-2484.5
-625.2
-319.1
-208.1
-289.3
-270.9
-338.2
-140.6
-24.5
-44.3
-14
-9.4
-29.4
-11.5
-13.2

cash-flows.row.free-cash-flow

145.51490.1-1359.2-486.4
-1478.1
-1438.9
338.9
272.9
186.6
29.8
167.7
-13.2
113.6
138.6
61.6
124.5
41.6
13.5
36.5
27.2

Income Statement Row

Luye Pharma Group Ltd.'s revenue saw a change of 0.027% compared with the previous period. The gross profit of 2186.HK is reported to be 4204.18. The company's operating expenses are 3175.45, showing a change of -0.351% from the last year. The expenses for depreciation and amortization are 671.31, which is a 0.045% change from the last accounting period. Operating expenses are reported to be 3175.45, which shows a -0.351% year-over-year change. Selling and marketing expenses are 0, which is a 0.000% change compared to the previous year. The EBITDA based on the recent numbers is 0, representing a -0.270% year-over-year growth. The operating income is 887.44, which shows a -0.270% change when compared to the previous year. The change in the net income is -0.119%. The net income for the last year was 532.61.

common:word.in-mln

USD
Growth
TTM20232022202120202019201820172016201520142013201120102009200820072006200520042003

income-statement-row.row.total-revenue

6143.086143.15981.75200.2
5539.6
6357.6
5173.4
3814.8
2917.8
2563.1
3154.2
2515.1
1774.4
1340.9
954.8
651
509
308.3
344.4
315.4
238.1

income-statement-row.row.cost-of-revenue

1938.91938.91841.11803.5
1549
1478.7
1124
851.5
535
475.7
482.5
413.5
301.1
204.2
136
85.9
80.2
63.5
76.5
105
108

income-statement-row.row.gross-profit

4204.184204.24140.53396.7
3990.6
4878.9
4049.4
2963.4
2382.7
2087.4
2671.7
2101.6
1473.3
1136.6
818.8
565.1
428.8
244.8
267.9
210.4
130.1

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

586.16---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

643.97---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

2056.17---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

00.3-73.3155.2
-199.9
-121
7.8
3.9
3.1
3.3
0.7
-0.2
126.2
1.1
11.6
13
-10
4.9
-1
-6.3
-6.9

income-statement-row.row.operating-expenses

3038.593175.43186.63113.9
2775.4
3019.2
2532.6
1872.5
1468
1256.5
1946.8
1687.8
1257.9
934.8
656.8
484.2
351.8
164.2
176.5
128.4
72.1

income-statement-row.row.cost-and-expenses

4977.495114.45027.84917.4
4324.4
4497.8
3656.6
2724
2003.1
1732.2
2429.4
2101.3
1559
1139
792.8
570.1
432
227.7
253
233.4
180.1

income-statement-row.row.interest-income

465.49117.188.7102
110.4
95.9
62.7
27.6
47.7
21.8
25.2
3
4.8
3.8
2.6
3.2
0
0
0
0
0

income-statement-row.row.interest-expense

347.02675.5471.8399.5
424
274.6
170.6
50.4
30.4
15.6
39.5
23.9
19.6
11.3
9.9
14.2
0
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

2056.17---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-187.34-187.3-545.2-461.5
-476.8
-218.3
-43.3
25.5
60
67.2
0.6
-30.6
-14.3
-6.5
4.2
1.9
-10
4.9
-1
-6.3
-6.9

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

00.3-73.3155.2
-199.9
-121
7.8
3.9
3.1
3.3
0.7
-0.2
126.2
1.1
11.6
13
-10
4.9
-1
-6.3
-6.9

income-statement-row.row.total-operating-expenses

-187.34-187.3-545.2-461.5
-476.8
-218.3
-43.3
25.5
60
67.2
0.6
-30.6
-14.3
-6.5
4.2
1.9
-10
4.9
-1
-6.3
-6.9

income-statement-row.row.interest-expense

347.02675.5471.8399.5
424
274.6
170.6
50.4
30.4
15.6
39.5
23.9
19.6
11.3
9.9
14.2
0
0
0
0
0

income-statement-row.row.depreciation-and-amortization

634.89701.9671.3582
510.9
442
317.2
249.8
140.9
115.2
110.4
100.4
79
70.2
44.8
16.1
41.2
15.1
11.7
11.1
10.3

income-statement-row.row.ebitda-caps

1522.33---
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

887.44887.41215387
1419
1989.9
1516.8
1090.8
1203.1
1103.6
764.8
406.3
215.4
201.9
162
80.8
77
80.6
91.4
82
58

income-statement-row.row.income-before-tax

700.1700.1669.8-74.6
942.2
1771.7
1473.5
1116.3
974.7
898.1
725.5
383.2
201.1
195.4
166.2
82.8
67
85.5
90.4
75.7
51.1

income-statement-row.row.income-tax-expense

161.0216186.570.2
238.9
279.8
167.5
135.8
80.7
133.4
111.1
55.2
34.9
45
37
20.7
8
4.6
0.2
-0.5
6.3

income-statement-row.row.net-income

532.61532.6604.8-144.8
706.6
1468.6
1303.4
981.4
891.5
754.5
605.5
310.5
151.6
136.1
123.5
62.1
59
80.9
90.2
71.8
42.6

Frequently Asked Question

What is Luye Pharma Group Ltd. (2186.HK) total assets?

Luye Pharma Group Ltd. (2186.HK) total assets is 25490715000.000.

What is enterprise annual revenue?

The annual revenue is 3238970000.000.

What is firm profit margin?

Firm profit margin is 0.684.

What is company free cash flow?

The free cash flow is 0.039.

What is enterprise net profit margin?

The net profit margin is 0.087.

What is firm total revenue?

The total revenue is 0.144.

What is Luye Pharma Group Ltd. (2186.HK) net profit (net income)?

The net profit (net income) is 532605000.000.

What is firm total debt?

The total debt is 8423947000.000.

What is operating expences number?

The operating expences are 3175450000.000.

What is company cash figure?

Enretprise cash is 5654804000.000.